Company intelligence / Profile preview

PhysioStim

Ownership: Private
Employees: ~25
Development stage: Other

Overview

PhysioStim is a specialized contract research organization (CRO) providing expert services in cardiovascular safety pharmacology and electrophysiology. Based in France, the company offers GLP-compliant assays to evaluate the cardiac safety profiles of drug candidates, including hERG testing and comprehensive ion channel screening. Their technical capabilities span manual and automated patch-clamp, as well as ex vivo tissue models like the Langendorff heart preparation. In May 2024, PhysioStim was acquired by Sygnature Discovery, integrating its safety pharmacology expertise into a broader drug discovery service offering. The company serves a global client base ranging from small biotechs to large pharmaceutical corporations.

Industry: Contract Research Organization

Beyond the preview

Go deeper on PhysioStim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhysioStim.

Explore the full profile